CClinicalTrials.gg
Sign In
CompletedNCT07357818Updated Aug 6, 2026

Effects of Caffeinated Beverages on Well-being

An interventional study of Participants' typical caffeinated beverage and Test caffeinated beverage in Healthy, Caffeine and Beverage Intake, sponsored by GUAYAKI SUSTAINABLE RAINFOREST PRODUCTS, INC.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by GUAYAKI SUSTAINABLE RAINFOREST PRODUCTS, INC. · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will evaluate post-beverage subjective caffeine responses and physiological responses to caffeinated beverages in generally healthy adults.

Read the detailed description

This will evaluate post-beverage subjective caffeine responses using visual analog scale questionnaires, mood, quality of life, and physiological responses to caffeine beverages compared to participants' habitual caffeine beverage intake in generally healthy adults.

02

Conditions studied

  • Healthy
  • Caffeine
  • Beverage Intake

Keywords

  • Caffeine beverages in health and well-being
03

In context

Lead sponsor

GUAYAKI SUSTAINABLE RAINFOREST PRODUCTS, INC. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Males or females, ≥18 to ≤55 years of age
  2. BMI ≥18.5 and \<29.9 kg/m2
  3. Generally good health
  4. Participant currently and consistently has a caffeine routine
  5. Participant is willing to substitute their current caffeine routine for the test beverage daily
  6. Participant has never consumed the test beverage or similar products
  7. Participant currently owns a wearable and is willing to use and connect the wearable device
  8. Willing to use personal smart phone, tablet, or personal computer with stable internet connection
  9. Willing and able to comply with all study procedures
  10. Willing to adhere to all study procedures, including lifestyle considerations and sign forms providing informed consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. History or presence, on the basis of the health history, of clinically important condition or disease states
  2. Is currently following, or planning to be on, a weight loss regimen
  3. Weight loss or gain >4.5 kg
  4. History of gastrointestinal surgery for weight reducing purposes or gastrointestinal (GI) conditions
  5. History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) at the discretion of the Clinical Investigator.
  6. History of unconventional sleep patterns (e.g., night shift) or diagnosed sleep disorder
  7. Use of tobacco/nicotine products
  8. Use of hemp/marijuana products
  9. Unstable use of any prescription medication
  10. Use of any medications(s) or dietary supplement(s), containing caffeine, or interacting with caffeine
  11. Recent history of alcohol or substance abuse
  12. Exposed to any non-registered drug product
  13. Self-report of hypertension/high blood pressure without use of hypertensive medications
  14. Any known allergy or intolerance to any ingredients contained in the study product
  15. Any signs or symptoms of active infection of clinical relevance
  16. History or presence of cancer, except for non-melanoma skin cancer
  17. History of any major trauma or major surgical event
  18. Female who is pregnant, planning to be pregnant during the study period, lactating
  19. An employee, close relative of an employee, or participant who has a financial interest in Sponsor company or any other caffeine beverage company.
  20. Any condition the Investigator believes would interfere with the participant's ability to provide informed consent or comply with the study protocol
  21. A clinically significant medical condition that is affected by caffeine
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Other
    Test caffeinated beverage followed by participants' typical caffeinated beverage

    Other: Participants' typical caffeinated beverage · Other: Test caffeinated beverage

  • Other
    Participants' typical caffeinated beverage followed by test caffeinated beverage

    Other: Participants' typical caffeinated beverage · Other: Test caffeinated beverage

Interventions

  • OtherParticipants' typical caffeinated beverage

    Participants will consume the caffeinated beverage they typically consume.

  • OtherTest caffeinated beverage

    Participants will consume a test beverage that contains caffeine.

06

What researchers measure

Primary outcomes

  1. Subjective caffeine visual analog scales

    Participants will rate how they feel on a horizontal line. Lines will be flanked with perceived feelings. Scores range from 0-100, where a higher score indicates increase in that feeling.

    Time frame: After 5 days of daily consumption

Secondary outcomes

  1. Subjective caffeine visual analog scales

    Participants will rate how they feel on a horizontal line. Lines will be flanked with perceived feelings. Scores range from 0-100, where a higher score indicates increase in that feeling.

    Time frame: Up to 5 hours after beverage consumption

  2. Subjective quality of life ratings

    Participants will rate how they feel using a Likert scale from 0-5. Where higher score indicate higher frequency in that feeling.

    Time frame: After 5 days of daily consumption

Other outcomes

  1. Physiological responses - Heart rate

    Data collected by wearables

    Time frame: Up to 5 hours post-beverage consumption and after 5 days of daily beverage consumption

  2. Subjective beverage experience ratings

    Participants will rate how they feel on a horizontal line. Lines will be flanked with perceived feelings. Scores range from 0-100, where a higher score indicates increase in that feeling.

    Time frame: After 5 days of daily consumption

  3. Physiological response - Sleep

    Data collected by wearables

    Time frame: Up to 5 hours post-beverage consumption and after 5 days of daily beverage consumption

  4. Physiological responses - Activity

    Data collected by wearables

    Time frame: Up to 5 hours post-beverage consumption and after 5 days of daily beverage consumption

07

Study locations

1 site
  • Alethios, Inc.
    San Francisco, California 94109, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07357818
Lead sponsor
GUAYAKI SUSTAINABLE RAINFOREST PRODUCTS, INC.
Collaborators
Nlumn LLC, Alethios, Inc.
Responsible party
Sponsor
First posted
Jan 22, 2026
Start date
Nov 3, 2025
Primary completion
Mar 23, 2026
Completion
Mar 23, 2026
Last update
Aug 6, 2026

Study contacts

Kristin Nieman, PhD
principal investigator · Nlumn LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

GUAYAKI SUSTAINABLE RAINFOREST PRODUCTS, INC.

Start the discussion